Table 3.
Cardiovascular findings according to oncologic diagnosis.
| Cardiovascular parameters |
Total N = 79 |
Hodgkin lymphoma N = 20 |
Sarcoma N = 17 |
ALL N = 24 |
Relapse ALL N = 10 |
Others* N = 8 |
p |
|---|---|---|---|---|---|---|---|
| CPET | |||||||
| VO2 max (% norm) | 91 ± 21 | 94 ± 26 | 79 ± 13 | 96 ± 19 | 89 ± 20 | 92 ± 24 | nsd |
| Laboratory | |||||||
| NTproBNP (ng/dL) | 40 [6-763] | 40 [6-168] | 130 [17-763] | 33 [8-77] | 37 [7-139] | 54 [15-273] | 0.043d |
| NTproBNP elevateda | 18/65 (28) | 5/19 (26) | 10/15 (67) | 0/17 | 2/9 (22) | 1/5 (20) | 0.001e |
| n/N (%) | |||||||
| cTNT (ng/dL) | 0.004 [0.001-0.10] | 0.004 [0.003-0.10] | 0.006 [0.001-0.009] | 0.003 [0.003-0.008] | 0.005 [0.003-0.01] | 0.003 [0.003-0.006] | nsd |
| TTE morphology | |||||||
| Myocardial hypertrophyb; | 0/79 | 0/20 | 0/17 | 0/24 | 0/10 | 0/8 | NA |
| n/N (%) | |||||||
| LV dilatationc | 1/79 (1) | 0/20 | 1/17 (6) | 0/24 | 0/10 | 0/8 | nse |
| n/N (%) | |||||||
| TTE systolic function | |||||||
| EF (%) | 62 ± 7 | 63 ± 7 | 60 ± 8 | 63 ± 7 | 65 ± 8 | 61 ± 6 | nsd |
| GLS | −18.7 [−22.6 to −10.0] | −20.1 [−22.6 to −14.8] | −17.0 [−21.0 to −10.0] | −18.4 [−22.6 to −15] | −18.5 [−22.1 to −14.8] | −19.2 [−20.0 to −16.5] | nsd |
| TTE diastolic function | |||||||
| LA volume/BSA (ml/m2) | 16.1 ± 3.9 | 16.0 ± 3.4 | 17.9 ± 4.2 | 15.3 ± 4.0 | 14.4 ± 4.2 | 17.0 ± 2.3 | nsd |
| MV E/A ratio | 1.6 [1.0–3.3] | 1.4 [1.0–2.1] | 1.6 [1.0–3.1] | 1.6 [1.0–3.3] | 1.3 [1.0–3.0] | 1.7 [1.5–2.3] | nsd |
| MV E dec (ms) | 175 ± 37 | 179 ± 47 | 171 ± 32 | 183 ± 32 | 162 ± 33 | 167 ± 40 | nsd |
| MV E/E' sept | 6.0 [3.4–17.2] | 5.3 [3.8–7.6] | 6.9 [3.8–17.2] | 5.3 [3.4–7.7] | 7 [5.4–15.0] | 6.5 [3.7–8.4] | 0.006d |
| MV E/E' sept abnormal; | 8/72 (11) | 0/18 | 4/15 (27) | 0/23 | 3/10 (30) | 1/6 (17) | 0.001e |
| n/N (%) | |||||||
| CMR | |||||||
| LGE positive; | 0 | 0 | 0 | 0 | 0 | 0 | NA |
| n/N (%) | |||||||
| T1 ECV | 22 ± 2 | 20 | 22 ± 2 | NA | 21 ± 1 | 25 ± 1 | nsd |
| Any cardiovascular abnormality | |||||||
| n/N (%) | 38/79 (48) | 9/20 (45) | 14/17 (82) | 5/24 (21) | 5/10 (50) | 5/8 (63) | 0.003 e |
Data are shown as mean ± standard deviation or median [range] according to data distribution.
Other oncologic diagnosis include nephroblastoma (N = 4), neuroblastoma (N = 3), and hepatoblastoma (N = 1).
NTproBNP elevated defined by values >100 ng/dL.
Myocardial hypertrophy defined by left ventricular enddiastolic posterior wall z-score >2.
Left ventricular dilatation defined by left ventricular enddiastolic diameter z-score >2.
ANOVA (analysis of variances) or Kruskall-Wallis-test according to data distribution.
Pearson chi square.
N, number of patients; ns, not significant; NA, not available; ng, nanogram; dL, deciliter; CPET, cardiopulmonary exercise testing; VO2 max (% norm), peak respiratory oxygen uptake in % predicted; NTproBNP, N-terminal pro-brain natriuretic peptide; cTNT, cardiac troponin T; TTE, transthoracic echocardiography; LV, Left ventricular; EF, Ejection Fraction; GLS, Global longitudinal strain; LA, left atrium; BSA, body surface area; MV, Mitral valve; CMR, cardiovascular magnetic resonance imaging; LGE, Late gadolinium enhancement; ECV, extracellular volume fraction.